A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2032-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center phase III study to compare the clinical benefit of androgen
deprivation therapy with or without docetaxel with or without local radiotherapy with or
without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate
cancer.
Phase:
Phase 3
Details
Lead Sponsor:
UNICANCER
Collaborators:
European Organisation for Research and Treatment of Cancer - EORTC Ipsen Janssen-Cilag Ltd. Sanofi